Literature DB >> 11166731

A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells.

H C Weber1, J Walters, J Leyton, M Casibang, S Purdom, R T Jensen, D H Coy, C Ellis, G Clark, T W Moody.   

Abstract

A synthetic peptide, (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) was used to investigate the signal transduction mechanisms of bombesin receptor subtype-3. Using NCI-1299#5 human lung cancer cells stably transfected with bombesin receptor subtype-3, 100 nM (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) elevated the cytosolic Ca2+ from 150 to 250 nM within 10 s. Addition of (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) caused phosphorylation of mitogen activated protein kinase in a time- and concentration-dependent manner. The mitogen activated protein kinase phosphorylation caused by (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) was inhibited by 2'-amino-3'-methyoxyflavone (PD98059), a mitogen activated protein kinase kinase (MEK-1) inhibitor. Using a luciferase reporter gene construct, (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) caused Elk-1 activation after 10 min and the increase in Elk-1 activation caused by (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) was inhibited by PD98059 as well as a dominant-negative MEK-1. (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) caused increased c-fos as well as c-jun mRNAs 1 h after addition to NCI-H1299#5 cells. The 47-fold increase in c-fos mRNA caused by 100 nM (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) was inhibited by PD98059, a dominant-negative MEK-1 and a substance P antagonist but not (3-phenylpropanoyl-D-Ala(24), Pro(26), Psi(26,27), Phe(27))GRP-(20-27) (BW2258U89), a GRP receptor antagonist. These results indicate that (D-Phe(6), beta-Ala(11), Phe(13), Nle(14))bombesin-(6-14) caused increased nuclear oncogene expression and upstream events include mitogen activated protein kinase phosphorylation and Elk-1 activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166731      PMCID: PMC8855643          DOI: 10.1016/s0014-2999(00)00941-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

1.  Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.

Authors:  S A Mantey; H C Weber; E Sainz; M Akeson; R R Ryan; T K Pradhan; R P Searles; E R Spindel; J F Battey; D H Coy; R T Jensen
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3.

Authors:  R R Ryan; H C Weber; W Hou; E Sainz; S A Mantey; J F Battey; D H Coy; R T Jensen
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2.

Authors:  M Kortenjann; O Thomae; P E Shaw
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

4.  Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor.

Authors:  E R Spindel; E Giladi; P Brehm; R H Goodman; T P Segerson
Journal:  Mol Endocrinol       Date:  1990-12

5.  Characterization of a mitogen-activated, Ca2+-sensitive microtubule-associated protein-2 kinase.

Authors:  M Hoshi; E Nishida; H Sakai
Journal:  Eur J Biochem       Date:  1989-09-15

6.  [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.

Authors:  S Mahmoud; J Staley; J Taylor; A Bogden; J P Moreau; D Coy; I Avis; F Cuttitta; J L Mulshine; T W Moody
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

7.  cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor.

Authors:  E Wada; J Way; H Shapira; K Kusano; A M Lebacq-Verheyden; D Coy; R Jensen; J Battery
Journal:  Neuron       Date:  1991-03       Impact factor: 17.173

8.  Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.

Authors:  J K Westwick; A D Cox; C J Der; M H Cobb; M Hibi; M Karin; D A Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells.

Authors:  R R Ryan; H C Weber; S A Mantey; W Hou; M E Hilburger; T K Pradhan; D H Coy; R T Jensen
Journal:  J Pharmacol Exp Ther       Date:  1998-10       Impact factor: 4.030

10.  Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells.

Authors:  M Draoui; P Chung; M Park; M Birrer; S Jakowlew; T W Moody
Journal:  Peptides       Date:  1995       Impact factor: 3.750

View more
  11 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

2.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

3.  A selective human bombesin receptor subtype-3 peptide agonist mediates CREB phosphorylation and transactivation.

Authors:  Xiaoqun Qin; Xiangping Qu; David Coy; H Christian Weber
Journal:  J Mol Neurosci       Date:  2011-11-30       Impact factor: 3.444

4.  Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Authors:  Terry W Moody; Veronica Sancho; Alessia di Florio; Bernardo Nuche-Berenguer; Samuel Mantey; Robert T Jensen
Journal:  Peptides       Date:  2011-06-25       Impact factor: 3.750

5.  ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.

Authors:  Terry W Moody; Samuel A Mantey; Paola Moreno; Taichi Nakamura; Enza Lacivita; Marcello Leopoldo; Robert T Jensen
Journal:  Peptides       Date:  2014-12-30       Impact factor: 3.750

6.  Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.

Authors:  Ana M Bajo; Andrew V Schally; Magdalena Krupa; Francine Hebert; Kate Groot; Karoly Szepeshazi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Authors:  Hans-Peter Lammerich; Annette Busmann; Christian Kutzleb; Martin Wendland; Petra Seiler; Claudia Berger; Peter Eickelmann; Markus Meyer; Wolf-Georg Forssmann; Erik Maronde
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

8.  Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.

Authors:  Irene Ramos-Álvarez; Taichi Nakamura; Samuel A Mantey; Paola Moreno; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Peptides       Date:  2015-10-31       Impact factor: 3.750

9.  A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Authors:  Paola Moreno; Samuel A Mantey; Suk H Lee; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Peptides       Date:  2018-02-02       Impact factor: 3.750

Review 10.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.